ClinicalTrials.gg
RecruitingNCT07361887(WINEVOME)Updated Jan 23, 2026

Deciphering the Effect of Moderate Wine Consumption on Healthy Aging Through Postprandial Extracellular Vesicles.

An interventional study of White Wine and Red Wine in Atherosclerosis Cardiovascular Disease, Obesity and Metabolic Syndrome, sponsored by University of Seville. Recruiting at 1 site in Spain. Open to participants aged 35 Years to 36 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-23.

Sponsored by University of Seville · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
8
Allocation
Randomized
Ages
35 Years to 36 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 390 studies in Obesity with a site in Spain — 95 open to participants now, 134 under way, 45 of them phase 3. Obesity · Spain.

Planned enrollment
331st of 332
8 · median 124
Started
2025
with 51 others
No phase
220 of 390
41 open now
Primary completion
2025-12
later than 28 of 133 live
Registered
337th of 390
by date

Among the 390 studies in Obesity with a site in Spain, this one is the 331st largest by planned enrollment of the 332 interventional ones that give a count, is one of 52 that started in 2025, is one of 220 with no phase, reaches primary completion later than 28 of the 133 other live ones, and was the 337th registered.

Obesity

11,564 studies on the registry are indexed under Obesity; 2,063 are open to participants now.

Browse Obesity studies →

Open to participants now

95 of the 390 studies in Obesity with a site in Spain are open now. Recruiting first, the newest first:

90 more — sign in →

All 95 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 1,352 Obesity studies recruiting now, 382 (28%) set no upper age limit and 867 (64%) stop at 75 or younger; 169 take children under 18; 491 take healthy volunteers.

This study: 35 Years to 36 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 390 studies in Obesity with a site in Spain, or all of them as a file.
02

Study summary

This study aims to investigate how moderate wine consumption influences circulating extracellular vesicles (EVs) in healthy adults. EVs are small particles released by cells that carry proteins, lipids, and genetic material, and play important roles in communication between cells. Participants will consume a single serving of red or white wine, and blood samples will be collected before and after consumption to study changes in the composition and function of EVs. The study will also assess how these EVs affect vascular, immune, and brain-related cells. The results are expected to improve our understanding of how moderate wine intake contributes to cardiovascular and brain health.

Read the detailed description

Dietary interventions have been consistently proposed as a part of a comprehensive strategy to lower the incidence and severity of atherosclerosis and coronary vascular disease. According to the Dietary Guidelines for Americans 2015-2020, moderate red wine consumption-defined as up to two units of alcohol per day for men and up to one unit of alcohol per day for women-significantly reduces the risk of cardiovascular disease (CVD). Wine is a complex matrix consisting primarily of water (86%) and ethyl alcohol (12%), as well as other different molecules, such as polyphenols, organic acids, tannins, compound minerals, vitamins and biologically active compounds. While most of the nutritional studies have focused on elucidating the mechanisms by which biologically active compounds directly affect cardiovascular-related events, little or nothing is known about the regulatory effect of wine consumption on extracellular vesicles (EVs). EVs are small phospholipid particles that convey molecular bioactive cargoes and play essential roles in intercellular communication and, hence, a multifaceted role in health and disease. Recent advances in research on EVs have significantly enhanced their potential as therapeutic agents for neurological diseases. Owing to their therapeutic properties and ability to cross the blood-brain barrier (BBB), extracellular vesicles are recognized as promising drug delivery vehicles (e.g. polyphenols) for various neurological conditions. For the first time, the purpose of this project is to establish whether the moderate wine consumption may alter the structure, cargo, and functionality of postprandial EVs. In the precision nutrition era, we expect to offer a new insight on EVs and their relationship with wine through the following objectives: 1) To map changes in the lipidome, proteome, polyphenolic cargo, and functional properties of circulating EVs in healthy subjects both at fasting and at postprandial state upon a challenge of a one unit of red or white wine; 2) To analyse the effect of postprandial EVs on atherosclerotic-related events in endothelial and immune cells. 3) To analyse the effect of postprandial EVs on healthy ageing in blood-brain barrier and microglial cells. Collectively, this project will provide fundamental insight into EV biology and remarks the clinical and functional relevance and consequences of moderate wine consumption in health and disease.

03

Conditions studied

  • Atherosclerosis Cardiovascular Disease
  • Obesity
  • Metabolic Syndrome
  • Metabolic Disorders
  • Inflammation
  • Neurodegeneration
  • Neurodegenerative Disease
  • Alzheimer s Disease

Keywords

  • blood-brain barrier
  • microglia
  • extracellular vesicles
  • lipidome
  • proteome
  • vascular disease
04

Who can participate

Ages eligible
35 Years to 36 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult men and women aged 35 to 65 years.
  • (BMI) between 18.5 and 29.9 kg/m².
  • Non-smokers or ex-smokers for at least 12 months.
  • Moderate alcohol consumers, defined as ≤2 units/day for men and ≤1 unit/day for women.
  • Normal fasting glucose and lipid profile at screening.
  • Willing and able to refrain from alcohol, polyphenol-rich foods, and intense exercise for 48 hours before each study visit.
  • Able to understand the study procedures and provide written .

Exclusion criteria

Exclusion Criteria

  • History or clinical evidence of cardiovascular, hepatic, renal, thyroid, gastrointestinal, or metabolic diseases (including diabetes, dyslipidemia, or hypertension).
  • Use of medications or supplements known to affect glucose, lipid, or inflammatory metabolism (e.g., statins, , anti-inflammatory drugs).
  • Pregnancy or breastfeeding.
  • Recent blood donation (within the last 3 months) or planned blood donation during the study period.
  • Major weight change (>5% of body weight) within the last 3 months.
  • Participation in another clinical or biomedical study within the previous 3 months.
  • Known allergy or intolerance to wine, alcohol, or its components (e.g., sulfites).
  • History of alcohol abuse or inability to abstain from alcohol outside the study context.
  • Reluctance to receive information about incidental health findings arising from the study.
  • Any condition judged by the investigators to limit compliance or increase study risk (e.g., psychiatric disorders, inability to adhere to fasting requirements).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Single (Participant)
Enrollment
8 participants (estimated)

Study arms

  • Experimental
    Red Wine

    Participants will consume red wine (Cabernet Sauvignon) at a dose of 4 mL per kg body weight within 15 minutes. Blood samples will be collected at fasting (0 h), postprandial peak (1-2 h), and post-peak (6 h).

    Dietary Supplement: Red Wine

  • Experimental
    White Wine

    Participants will consume white wine (Chardonnay) at a dose of 4 mL per kg body weight within 15 minutes. Blood samples will be collected at fasting (0 h), postprandial peak (1-2 h), and post-peak (6 h).

    Dietary Supplement: White Wine

  • Placebo comparator
    Water (Control)

    Participants will consume water (4 mL per kg body weight) within 15 minutes, serving as the control condition. Blood samples will be collected at fasting (0 h), postprandial peak (1-2 h), and post-peak (6 h).

    Dietary Supplement: Water

Interventions

  • Dietary supplementWhite Wine

    Chardonnay, 4 mL/kg body weight

  • Dietary supplementRed Wine

    Cabernet Sauvignon, 4 mL/kg body weight

  • Dietary supplementWater

    Still water, 4 mL/kg body weight

06

What researchers measure

Primary outcomes

  1. Concentration of circulating extracellular vesicles

    Concentration of plasma-derived extracellular vesicles measured after acute intake of red wine, white wine, or water. Extracellular vesicles will be isolated by immunoaffinity methods and quantified using nanoparticle-based analysis. Results will be expressed as particles per milliliter (particles/mL).

    Time frame: Baseline (0 hours), postprandial peak (2 hours after beverage intake), and post-peak (6 hours after beverage intake).

  2. Mean size of circulating extracellular vesicles

    Mean diameter of plasma-derived extracellular vesicles measured after acute intake of red wine, white wine, or water. Extracellular vesicle size will be assessed using dynamic light scattering. Results will be expressed in nanometers (nm).

    Time frame: Baseline (0 hours), postprandial peak (2 hours after beverage intake), and post-peak (6 hours after beverage intake).

Secondary outcomes

  1. Postprandial changes in extracellular vesicle proteome

    Postprandial changes in the protein composition of plasma-derived extracellular vesicles following acute intake of red wine, white wine, or water. EV-associated proteins will be analyzed using quantitative liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results will be expressed as normalized protein abundance.

    Time frame: Baseline (0 hours), postprandial peak (2 hours after beverage intake), and post-peak (6 hours after beverage intake).

  2. Postprandial changes in extracellular vesicle lipidome

    Postprandial changes in the lipid composition of plasma-derived extracellular vesicles following acute intake of red wine, white wine, or water. EV-associated lipid species will be analyzed using quantitative lipidomics by liquid chromatography-mass spectrometry (LC-MS). Results will be expressed as normalized lipid abundance.

    Time frame: Baseline (0 hours), postprandial peak (2 hours after beverage intake), and post-peak (6 hours after beverage intake).

  3. Change from baseline in plasma glucose concentration

    Venous blood plasma glucose concentration measured using a validated clinical chemistry assay (enzymatic method). Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: mg/dL

    Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake

  4. Change from baseline in plasma insulin concentration

    Venous blood plasma insulin concentration measured using a validated immunoassay. Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: µIU/mL

    Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake

  5. Change from baseline in plasma triglyceride concentration

    Venous blood plasma triglyceride concentration measured using a validated clinical chemistry assay (enzymatic method). Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: mg/dL

    Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake

  6. Change from baseline in plasma total cholesterol concentration

    Venous blood plasma total cholesterol concentration measured using a validated clinical chemistry assay (enzymatic method). Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: mg/dL

    Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake

  7. Change from baseline in plasma HDL cholesterol concentration

    Venous blood plasma HDL cholesterol concentration measured using a validated clinical chemistry assay (enzymatic method). Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: mg/dL

    Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake

  8. Change from baseline in plasma LDL cholesterol concentration

    Venous blood plasma LDL cholesterol concentration measured using a validated clinical chemistry assay (enzymatic method). Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: mg/dL

    Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake

  9. Change from baseline in plasma interleukin-6 (IL-6) concentration

    Venous blood plasma IL-6 concentration measured using a validated immunoassay. Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: pg/mL

    Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake

  10. Change from baseline in plasma tumor necrosis factor alpha (TNF-α) concentration

    Venous blood plasma TNF-α concentration measured using a validated immunoassay. Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: pg/mL

    Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake

  11. Change from baseline in plasma interleukin-1 beta (IL-1β) concentration

    Venous blood plasma IL-1β concentration measured using a validated immunoassay. Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: pg/mL

    Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake

  12. Change from baseline in plasma monocyte chemoattractant protein-1 (MCP-1/CCL2) concentration

    Venous blood plasma MCP-1/CCL2 concentration measured using a validated immunoassay. Primary metric is change from baseline at each postprandial time point (time point value minus baseline value). Unit of Measure: pg/mL

    Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake

  13. Transendothelial electrical resistance (TEER) in an in vitro human blood-brain barrier model after exposure to postprandial extracellular vesicles

    lood-brain barrier (BBB) integrity assessed by transendothelial electrical resistance (TEER) in a human in vitro BBB model after exposure to extracellular vesicles (EVs) isolated from plasma at baseline (0 hours) and postprandial peak (2 hours). Unit of Measure: Ω·cm²

    Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; TEER assessed within 72 hours after EV isolation

  14. Claudin-5 (CLDN5) protein expression in an in vitro human blood-brain barrier model after exposure to postprandial extracellular vesicles

    Tight junction protein expression assessed in the BBB model by Claudin-5 (CLDN5) protein abundance after exposure to EVs isolated at baseline (0 hours) and 2 hours post intake. Protein expression quantified using immunoblotting or immunofluorescence and reported relative to the control condition. Unit of Measure: Fold change (dimensionless)

    Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; protein expression assessed within 72 hours after EV isolation

  15. Occludin (OCLN) protein expression in an in vitro human blood-brain barrier model after exposure to postprandial extracellular vesicles

    Tight junction protein expression assessed in the BBB model by occludin (OCLN) protein abundance after exposure to EVs isolated at baseline (0 hours) and 2 hours post intake. Protein expression quantified using immunoblotting or immunofluorescence and reported relative to the control condition. Unit of Measure: Fold change (dimensionless)

    Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; protein expression assessed within 72 hours after EV isolation

  16. Interleukin-6 (IL-6) concentration in microglial culture supernatant after exposure to postprandial extracellular vesicles

    Microglial activation assessed by IL-6 concentration in culture supernatant after exposure to EVs isolated at baseline (0 hours) and 2 hours post intake. Cytokine concentration quantified using a validated immunoassay. Unit of Measure: pg/mL

    Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; cytokines assessed within 72 hours after EV isolation

  17. Tumor necrosis factor alpha (TNF-α) concentration in microglial culture supernatant after exposure to postprandial extracellular vesicles

    Microglial activation assessed by TNF-α concentration in culture supernatant after exposure to EVs isolated at baseline (0 hours) and 2 hours post intake. Cytokine concentration quantified using a validated immunoassay. Unit of Measure: pg/mL

    Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; cytokines assessed within 72 hours after EV isolation

  18. IL1B mRNA expression in microglia after exposure to postprandial extracellular vesicles

    Microglial activation assessed by IL1B mRNA expression after exposure to EVs isolated at baseline (0 hours) and 2 hours post intake. Gene expression quantified by RT-qPCR and reported as relative expression versus control condition. Unit of Measure: Fold change (dimensionless)

    Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; gene expression assessed within 72 hours after EV isolation

  19. Endothelial VCAM-1 protein expression after exposure to postprandial extracellular vesicles

    Endothelial activation assessed by VCAM-1 protein expression in cultured human umbilical vein endothelial cells after exposure to extracellular vesicles isolated from plasma at baseline (0 hours) and postprandial peak (2 hours). Protein expression quantified by immunoblotting or immunofluorescence and reported relative to control condition. Unit of Measure: Fold change (dimensionless)

    Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; assays conducted within 48 hours after EV isolation

  20. Polyphenolic content of extracellular vesicles after wine intake

    Identification and quantification of polyphenolic compounds encapsulated within plasma-derived extracellular vesicles following acute intake of red wine or white wine. Polyphenols will be analyzed using ultra-high-performance liquid chromatography coupled to quadrupole-Orbitrap mass spectrometry. Results will be expressed as normalized peak areas and concentrations relative to internal standards.

    Time frame: Baseline (0 hours), postprandial peak (2 hours after beverage intake), and post-peak (6 hours after beverage intake).

  21. Spearman correlation between EV cargo score and change from baseline in plasma glucose concentration

    Association assessed using Spearman rank correlation (ρ) between EV cargo score (PC1 derived from normalized EV proteomic and lipidomic features measured by mass spectrometry) and the systemic response measure defined as change from baseline in plasma glucose concentration at postprandial time points. The outcome measure is Spearman's ρ. Unit of Measure: Spearman's ρ (dimensionless)

    Time frame: Baseline (0 hours), 2 hours, and 6 hours after beverage intake (plasma glucose); EVs isolated at baseline (0 hours) and 2 hours after beverage intake

  22. Endothelial ICAM-1 protein expression after exposure to postprandial extracellular vesicles

    Endothelial activation assessed by ICAM-1 protein expression in cultured human umbilical vein endothelial cells after exposure to extracellular vesicles isolated from plasma at baseline (0 hours) and postprandial peak (2 hours). Protein expression quantified by immunoblotting or immunofluorescence and reported relative to control condition. Unit of Measure: Fold change (dimensionless)

    Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; assays conducted within 48 hours after EV isolation

  23. Nitric oxide (NO) production in endothelial cell culture supernatant after exposure to postprandial extracellular vesicles

    Endothelial response assessed by nitric oxide production after exposure to extracellular vesicles isolated from plasma at baseline (0 hours) and postprandial peak (2 hours). NO production quantified in culture supernatant using a validated colorimetric assay (e.g., nitrite/nitrate). Unit of Measure: µM

    Time frame: EVs isolated at baseline (0 hours) and 2 hours after beverage intake; assays conducted within 48 hours after EV isolation

07

Study locations

1 of 1 sites recruiting
  • Av. de Sánchez Pizjuán, s/n, 41009 Sevilla Facultad de Medicina . Universidad de Sevilla
    Seville, Sevilla 41009, Spain
    Recruiting
    • Sergio Montserrat de la Paz, Full Professor · Contactdelapaz@us.es · +34 605383541
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Dec 2025, 1 month.

Of 3,697 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 1 month is below that.

Counting every sponsor, half of 3,861 studies reached it within 22 months; a quarter within 9 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2025
First posted
Jan 23, 2026
StartActual
Nov 1, 2025
Primary completionActual
Dec 1, 2025
CompletionEst.
Mar 31, 2027
Last update
Jan 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07361887
Responsible party
Sergio Montserrat de la Paz (Full Professor, University of Seville) — Principal investigator
First posted
Jan 23, 2026
Start date
Nov 1, 2025
Primary completion
Dec 1, 2025
Completion
Mar 31, 2027 (estimated)
Last update
Jan 23, 2026

Study contacts

Sergio Montserrat-de la Paz, Full Professor
Contact
delapaz@us.es
+34 605383541

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion